1Fass R, Ofman JJ. Gastroesophageal reflux disease --should we adopt a new conceptual framework? Am J Gastroenterol, 2002, 97: 1901-1909.
2Kaplan-Machlis B, Spiegler GE, Revicki DA. Healthrelated quality of life in primary care patients with gastroesophageal reflux disease. Ann Pharmacother, 1999,33: 1032-1036.
3Wahlqvist P. Symptoms of gastroesophageal reflux disease, perceived productivity, and health-related quality of life. Am J Gastroenterol, 2001, 96 (8 Suppl): S57-S61.
4Kahrilas PJ, Fennerty MB, Joelsson B. High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial. Am J Gastroenterol, 1999, 94: 92-97.
5Ours TM, Fackler WK, Richter JE, Vaezi MF. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol,2003, 98: 545-550.
6Miner P Jr, Orr W, Filippone J, Jokubaitis L, Sloan S.Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol, 2002, 97: 1332-1339.
7Quigley EM. Factors that influence therapeutic outcomes in symptomatic gastroesophageal reflux disease. Am J Gastroenterol, 2003, 98 (3 Suppl): S24-S30.
8Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease -- current concepts and dilemmas. Am J Gatroenterol, 2001, 96: 303-314.
9Bardhan KD. Intermittent and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease. Am J Gastroenterol,2003, 98 (3 Suppl): S40-S48.
10Bammer T, Freeman M, Shahriari A, Hinder RA,DeVault KR, Achem SR. Outcome of laparoscopic antireflux surgery in patients with nonerosive reflux disease. J Gastrointest Surg, 2002, 6: 730-737.
